Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

1473 results about "Ester derivatives" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Esters are derivatives of acids obtained by the exchange of the replaceable hydrogen for alkyl radicals.

Treatment with Statin and Omega-3 Fatty Acids and a Combination Product Thereof

InactiveUS20060211763A1Significant degradationBiocideSenses disorderFatty acidStatine

A pharmaceutical composition in unit dose form, comprising an essentially homogeneous solution comprising a statin essentially dissolved in solvent system comprising natural or synthetic omega-3 fatty acids or pharmaceutically acceptable esters, derivatives, conjugates, precursors or salts thereof, or mixtures thereof, wherein less than 10% of the statin is undissolved in the solvent system.

Owner:RELIANT PHARMACEUTICALS INC

Hyperlipemia therapeutic agent

ActiveUS7022713B2Good effectBiocideMetabolism disorderAdditive ingredientPitavastatin

The present invention relates to a hyperlipemia therapeutic agent comprising pitavastatins and eicosapentaenoic acid or an ester derivative thereof as effective ingredients.According to the present invention, a type IIb and type IV hyperlipemia therapeutic agent having an excellent effect of lowering the cholesterol and triglyceride in blood is provided.

Hyperlipemia therapeutic agent

Owner:KOWA CO LTD +1

Biodegradable polyesters

InactiveUS6120895AMonocomponent copolyesters artificial filamentPolyurea/polyurethane coatingsFiberPolymer science

PCT No. PCT/EP97/04908 Sec. 371 Date Mar. 17, 1999 Sec. 102(e) Date Mar. 17, 1999 PCT Filed Sep. 19, 1997 PCT Pub. No. WO98/12242 PCT Pub. Date Mar. 20, 1998Biodegradable polyesters based on A) 95-99.99 mol % of at least one polyester A containing as monomeric building blocks of an acid component comprising a11) 20-95 mol % of at least one aliphatic or cycloaliphatic dicarboxylic acid or its ester-forming derivative and a12) 5-80 mol % of at least one aromatic dicarboxylic acid or its ester-forming derivative and at least one dihydroxy compound or at least one amino alcohol or their mixtures, and B) 0.01-5 mol % of a mixture comprising mono-, bi-, tri-, tetra- and higher-nuclear isocyanurates or corresponding compounds containing two, three or four functional groups capable of reacting with the end groups of polyester A, or mixtures of the isocyanurates and the corresponding compounds, as well as molding compositions comprising said polyesters, their manufacture and their use in the manufacture of moldings, filsm, fibers and coatings.

Owner:BASF AG

Surfactant, method of producing a fluoropolymer, fluoropolymer aqueous dispersion

InactiveUS20070142513A1Small diameterFibre treatmentPolymer scienceHydrogen atom

The present invention provides a surfactant making it possible to obtain particles comprising a fluoropolymer at a size smaller in diameter in an aqueous dispersion obtained by polymerization in the presence of the same. The present invention is a surfactant comprising a fluorine-containing-sulfobutanedioic-acid-ester derivative represented by the general formula (i): Y—Rf1—(CH2)m—OCOCH(SO3M)-CH2COO—(CH2)n—Rf2—Y (i) wherein Y represents hydrogen atom or fluorine atom; when Y is hydrogen atom, one of Rf1 and Rf2 is —(CF2CF2)3— and the other is —(CF2CF2)2— or —(CF2CF2)3— and, when Y is fluorine atom, Rf1 and Rf2 are the same or different and each is a divalent hydrocarbon group containing 1 to 4 carbon atoms and containing at least one fluorine atom; m and n are the same or different and each represents an integer of 1 to 3; and M represents NH4, Li, Na, K or H.

Surfactant, method of producing a fluoropolymer, fluoropolymer aqueous dispersion

Owner:DAIKIN IND LTD

Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring

ActiveUS20050119219A1BiocideOrganic active ingredientsControlled releaseHyaluronic acid

The present invention relates to hyaluronic acid ester derivatives, whose carboxylic groups are partially esterified with hydroxy groups of propiophenone derivatives, to the hydrogel materials consisting of the said hyaluronic acid ester derivatives, to their preparation process by photocuring of the hyaluronic acid ester derivatives, and their use in the biomedical, sanitary and surgical fields, and in the medical field as controlled release systems for drugs.

Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring

Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring

Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring

Owner:FIDIA FARM SPA

Substituted pyrazole derivatives, production process thereof, and herbicide compositions containing the derivatives

InactiveUS7192906B2BiocideOrganic chemistryPerylene derivativesHydrazide

Substituted pyrazole compounds of the formula (1). The compounds are synthesized from a pyrazole derivative and a haloalkyleneoxime ester derivative, and have excellent herbicidal effects. Herbicide compositions containing the substituted pyrazole derivatives or hydrazide derivatives thereof as active ingredients possess wide herbicidal spectra, work sufficiently in small dosages, and are sufficiently safe for certain important crops

Substituted pyrazole derivatives, production process thereof, and herbicide compositions containing the derivatives

Substituted pyrazole derivatives, production process thereof, and herbicide compositions containing the derivatives

Substituted pyrazole derivatives, production process thereof, and herbicide compositions containing the derivatives

Owner:SDS BIOTECH CO LTD

Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives

ActiveUS7601820B2BiocideSugar derivativesPurineMethyl group

The present invention provides (i) a process for preparing a 2-deoxy-2-fluoro-2-methyl-D-ribonolactone derivative, (ii) conversion of the lactone to nucleosides with potent anti-HCV activity, and their analogues, and (iii) a method to prepare the anti-HCV nucleosides containing the 2-deoxy-2-fluoro-2-C-methyl-β-D-ribofuranosyl nucleosides from a preformed, preferably naturally-occurring, nucleoside.

Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives

Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives

Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives

Owner:GILEAD SCI INC

Non-aqueous secondary battery

ActiveUS20060286459A1Final product manufactureOrganic electrolyte cellsElectrolytic agentSulfonate

A non-aqueous secondary battery contains a positive electrode, a negative electrode, a separator and a non-aqueous electrolytic solution. The positive electrode contains a layered structure lithium-containing compound oxide, or a spinel lithium-containing compound oxide containing manganese as an active material. The non-aqueous electrolytic solution contains at least one additive selected from a sulfonic acid anhydride, a sulfonate ester derivative, a cyclic sulfate derivative and a cyclic sulfonate ester derivative, and a vinylene carbonate or a derivative of the vinylene carbonate.

Non-aqueous secondary battery

Non-aqueous secondary battery

Non-aqueous secondary battery

Owner:MAXELL HLDG LTD

Self limiting catalyst composition and propylene polymerization process

ActiveUS7491670B2Poor surfaceOrganic-compounds/hydrides/coordination-complexes catalystsCatalyst activation/preparationSelf limitingElectron donor

A catalyst composition for the polymerization of propylene comprising one or more Ziegler-Natta procatalyst compositions comprising one or more transition metal compounds and one or more esters of aromatic dicarboxylic acid internal electron donors; one or more aluminum containing cocatalysts; a selectivity control agent (SCA) comprising at least one silicon containing compound containing at least one C1-10 alkoxy group bonded to a silicon atom, and one or more activity limiting agent (ALA) compounds comprising one or more aliphatic or cycloaliphatic carboxylic acids; alkyl-, cycloalkyl- or alkyl(poly)(oxyalkyl)-(poly)ester derivatives thereof; or inertly substituted derivatives of the foregoing.

Self limiting catalyst composition and propylene polymerization process

Owner:WR GRACE & CO CONN

Esters of capsaicin for treating pain

ActiveUS20080020996A1Reduce generationImprove lipophilicityAntibacterial agentsBiocideSolubilityIrritation

The present invention relates to the formulations of ester derivatives of capsaicin and ester derivatives of myristoleic acid. These derivatives are capable of reverting to the active parent compound following enzymatic or chemical hydrolysis. These derivatives have a higher lipophilicity, lipid solubility and less irritation to the skin than the parent compound, and hence are better able to be incorporated into certain pharmaceutical formulations, including cream and ointment pharmaceutical formulations. The pharmaceutical compositions of the present invention contain a compound of following formula (Ia):

R—CO-CAP (Ia)

wherein CAP refers to collectively the capsaicins represented in FIG. 1 and a compound of formula (Ib):

wherein MCO refers to myristoleic acid.

In formulae Ia and Ib, R is selected from alkyl groups of up to about 18 carbon atoms and aryl groups of up to about 18 carbon atoms and alkylene group of up to about 18 carbon atoms and an arylene group of up to about 18 carbon atoms. The alkyl, aryl and alkylene groups may be substituted or un-substituted, branched or straight chains. In addition, R may contain heteroatoms and may be straight chained or branched.

The pharmaceutical compositions containing compounds of formulae Ia and Ib are useful for pain management in mammals in vivo and have been contemplated to be used in the treatment of various pains in humans.

Esters of capsaicin for treating pain

Esters of capsaicin for treating pain

Esters of capsaicin for treating pain

Owner:TRINITY LAB INC

Cooling compositons

InactiveUS20040082654A1Cosmetic preparationsBiocideEthyl citrateEthyl ester

The present invention relates to cooling compositions comprising a cooling agent (preferably menthyl lactate) together with an ester derivative (preferably tri-ethyl citrate). Such compositions deliver immediate and long lasting freshness sensation, while maintaining or even improving skin and / or mucosal membrane health to which they are contacted and deodorizing said skin and / or mucosal membrane.

Cooling compositons

Cooling compositons

Cooling compositons

Owner:THE PROCTER & GAMBLE COMPANY

Cellulose interpolymers and method of oxidation

ActiveUS20050192434A1Decreasing and preventing frequencyPowder deliverySugar derivativesPolymer sciencePharmaceutical drug

This invention provides cellulose ester interpolymers, and methods of oxidizing cellulose interpolymers and cellulose ester interpolymers. The invention also provides routes to access carboxylated cellulose ester derivatives with high acid numbers wherein the carboxyl group is attached directly to the cellulose backbone by a carbon-carbon bond. Through functionalization of an intermediate aldehyde, the corresponding cationic or zwitterionic cellulose ester derivatives can also be accessed. The interpolymers of the present invention have a number of end-use applications, for example, as binder resins in various types of coating compositions and as drug delivery agents.

Cellulose interpolymers and method of oxidation

Cellulose interpolymers and method of oxidation

Cellulose interpolymers and method of oxidation

Owner:EASTMAN CHEM CO

Phosphonate-nucleotide ester derivatives

InactiveUS6037335AOrganic active ingredientsBiocideHydrogenHalogen

Phosphonate-nucleotide ester compounds of the formula (I) have excellent antiviral activity and antineoplastic activity. Further, they can be orally administered. wherein ring A represents wherein R1 and R2 independently represent hydrogen, halogen, hydroxyl, mercapto, C6-C10 arylthio or amino; R3 represents C1-C4 alkyl or ethyl having one or more substituents selected from the group consisting of fluorine, C1-C4 alkoxy, phenoxy, C7-C10 phenylalkoxy and C2-C5 acyloxy; R4 represents ethyl having one or more substituents selected from the group consisting of fluorine, C1-C4 alkoxy, phenoxy, C7-C10 phenylalkoxy and C2-C5 acyloxy; X, Y and Z independently represent methyne or nitrogen atom; or a pharmaceutically acceptable salt thereof.

Owner:MITSUBISHI CHEM CORP

Preparation of nucleosides ribofuranosyl pyrimidines

InactiveUS20080139802A1Efficient scalable processEasy to handleEsterified saccharide compoundsSugar derivativesCombinatorial chemistrySynthesis of nucleosides

The present process provides an improved method for converting 2′-deoxy-2′-fluoro-2′-methyl-D-ribonolactones derivatives to 3-fluoro-3-methyl-2-chlorofuran compounds which are useful for the synthesis of nucleosides and improved processes for the synthesis of the D-ribonolactone compounds.

Preparation of nucleosides ribofuranosyl pyrimidines

Preparation of nucleosides ribofuranosyl pyrimidines

Preparation of nucleosides ribofuranosyl pyrimidines

Owner:PHARMASSET +1

Dabigatran ester derivatives as prodrug

ActiveCN102050815AOrganic active ingredientsOrganic chemistryActive componentMedicinal chemistry

The invention relates to dabigatran ester derivatives as shown in a constitutional formula I, pharmaceutically acceptable nontoxic salts thereof, medical composite containing the compounds as active components, and application of thrombin inhibitor of the compounds and medical composites, wherein R1 represents H or C1 to C5 alkyl; R2 represents H, or C1 to C3 alkyl; and R3 represents C1 to C8 alkyl or substituted alkyl.

Dabigatran ester derivatives as prodrug

Dabigatran ester derivatives as prodrug

Dabigatran ester derivatives as prodrug

Owner:北京弘生医药科技有限公司

Coating for fertilizer

InactiveUS20050076687A1Maintain reaction temperatureImparts physical strengthBiocideGas treatmentVegetable oilPolymer chemistry

Method and apparatus for coating fertilizer in pellet or other form to impart time-release characteristics and the resulting coated pellet product. The polyurethane coating encapsulates fertilizer particles, forming a hydrophobic coating for slow-release qualities. The urethane polymer coating is formulated with an isocyanate and a combined fluid of a polyether polyol, a methyl ester derivative of plant or vegetable oil, a T-12 curing catalyst, barium sulfate, and an oil-based dye. The barium sulfate imparts physical strength to and enhances color quality of the polyurethane coating, and acts as a detackifier and maintains temperature in the coating reactor. The inventive formulation is effective in the practical polymer coating of sulfate-based or other fertilizer pellets in an inventive time-release fertilizer product. An apparatus is provided for carrying out the coating process.

Coating for fertilizer

Coating for fertilizer

Owner:WHITTINGTON PATSIE A

Catalyst for polyester production, process for producing polyester using the catalyst, polyester obtained by the process, and uses of the polyester

InactiveUS6451959B1Organic-compounds/hydrides/coordination-complexes catalystsCatalyst activation/preparationPolyesterDicarboxylic acid

The present invention provides a catalyst for polyester production capable of producing a polyester with high catalytic activity, a process for producing a polyester using the catalyst and a polyester produced thereby. The catalyst comprises a solid titanium compound obtained by dehydro-drying a hydrolyzate obtained by hydrolysis of a titanium halide and which has a molar ratio (OH / Ti) of a hydroxyl group (OH) to titanium (Ti) exceeding 0.09 and less than 4. In the process, the polyester is obtained by polycondensing an aromatic dicarboxylic acid, or an ester-forming derivative thereof, and an aliphatic diol, or ester-forming derivative thereof, in the presence of the catalyst. The resulting polyester has excellent transparency and tint, a titanium content of 1 to 100 ppm, a magnesium content of 1 to 200 ppm and a magnesium to titanium weight ratio of not less than 0.01.

Catalyst for polyester production, process for producing polyester using the catalyst, polyester obtained by the process, and uses of the polyester

Catalyst for polyester production, process for producing polyester using the catalyst, polyester obtained by the process, and uses of the polyester

Catalyst for polyester production, process for producing polyester using the catalyst, polyester obtained by the process, and uses of the polyester

Owner:MITSUI CHEM INC

Cyclic boronic acid ester derivatives and therapeutic uses thereof

ActiveUS20120040932A1Antibacterial agentsBiocideBoronic acidCombinatorial chemistry

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to 1 cyclic boronic acid ester derivatives and their use as therapeutic agents.

Cyclic boronic acid ester derivatives and therapeutic uses thereof

Cyclic boronic acid ester derivatives and therapeutic uses thereof

Cyclic boronic acid ester derivatives and therapeutic uses thereof

Owner:MELINTA SUBSIDIARY CORP

Injectable long-acting analgesic composition comprising an ester derivative of ketorolac

InactiveUS20060183786A1Good anti-inflammatory effectLong duration of actionBiocideAntipyreticKetorolacAryl radical

Disclosed herein is an injectable long-acting analgesic composition comprising:

(a) a ketorolac ester derivative of formula (I), wherein

- R is a straight-chain or branched saturated or unsaturated C₁-C₂₀aliphatic group optionally substituted with a C₆-C₁₀aryl group; and (b) a pharmaceutically acceptable oil vehicle. The composition can provide a longer duration of action and, therefore, is suitable for use in the treatment of long-lasting pains and inflammations.

Injectable long-acting analgesic composition comprising an ester derivative of ketorolac

Injectable long-acting analgesic composition comprising an ester derivative of ketorolac

Injectable long-acting analgesic composition comprising an ester derivative of ketorolac

Owner:CHI MEI MEDICAL CENT

Process for the manufacture of quinoline derivatives

InactiveUS7560557B2BiocideOrganic chemistryQuinolineCarboxylic acid

A process for the preparation of the compounds of general formula (I)whereinR is selected from methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec.-butyl and allyl;R5 is selected from methyl, ethyl, n-propyl, iso-propyl, methoxy, ethoxy, methylthio, ethylthio, n-propylthio, methylsulphinyl, ethylsulphinyl, fluoro, chloro, bromo, trifluoromethyl, and OCHxFy; wherein x=0-2, y=1-3 with the proviso that x+y=3; R6 is hydrogen; or R5 and R6 taken together are methylenedioxy; R′ is selected from hydrogen, methyl, methoxy, fluoro, chloro, bromo, trifluoromethyl, and OCHxFy, wherein x=0-2, y=1−3 with the proviso that x+y=3; R″ is selected from hydrogen, fluoro and chloro, with the proviso that R″ is selected from fluoro and chloro only when R′ is selected from fluoro and chloro; by reacting a quinoline-3-carboxylic acid ester derivative of formula A, where Z is methyl, with an aniline derivative of formula B according to the following reaction diagram, to give the compound of general formula (I), designated “C”, and an alcohol, designated “D”.in a solvent selected from straight or branched alkanes and cycloalkanes or mixtures thereof with a boiling point between 80 and 200° C.

Process for the manufacture of quinoline derivatives

Process for the manufacture of quinoline derivatives

Process for the manufacture of quinoline derivatives

Owner:ACTIVE BIOTECH AB

Esters of Capsaicin for Treating Pain

InactiveUS20110218180A1Improve lipophilicityNon-irritation to skinAntibacterial agentsBiocideSolubilityIrritation

The present invention relates to the formulations of ester derivatives of capsaicin and ester derivatives of myristoleic acid. These derivatives are capable of reverting to the active parent compound following enzymatic or chemical hydrolysis. These derivatives have a higher lipophilicity, lipid solubility and less irritation to the skin than the parent compound, and hence are better able to be incorporated into certain pharmaceutical formulations, including cream and ointment pharmaceutical formulations. The pharmaceutical compositions of the present invention contain a compound of following formula (Ia):R—CO—CAP (Ia)wherein CAP refers to collectively the capsaicins represented in FIG. 1 and a compound of formula (Ib):MCO—O—R (Ib)wherein MCO refers to myristoleic acid.In formulae Ia and Ib, R is selected from alkyl groups of up to about 18 carbon atoms and aryl groups of up to about 18 carbon atoms and alkylene group of up to about 18 carbon atoms and an arylene group of up to about 18 carbon atoms. The alkyl, aryl and alkylene groups may be substituted or un-substituted, branched or straight chains. In addition, R may contain heteroatoms and may be straight chained or branched.The pharmaceutical compositions containing compounds of formulae Ia and Ib are useful for pain management in mammals in vivo and have been contemplated to be used in the treatment of various pains in humans.

Esters of Capsaicin for Treating Pain

Esters of Capsaicin for Treating Pain

Esters of Capsaicin for Treating Pain

Owner:TRINITY LAB INC

Glycopeptide phosphonate derivatives

InactiveUS20020022590A1Antibacterial agentsPowder deliveryGlycopeptideAntibacterial agent

Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.

Glycopeptide phosphonate derivatives

Glycopeptide phosphonate derivatives

Glycopeptide phosphonate derivatives

Owner:CUMBERLAND PHARM INC

Non-aqueous electrolyte secondary battery

InactiveUS20080286657A1Improve charge and discharge cycle characteristicsLarge capacityAlkaline accumulatorsOrganic electrolyte cellsGraphiteSulfur containing

A non-aqueous electrolyte secondary battery is composed of a positive electrode containing a positive electrode active material capable of storing and releasing lithium ion, a negative electrode containing a negative electrode active material capable of storing and releasing lithium ion, and a non-aqueous electrolyte. The negative electrode active material contains a first material of a graphite material and a second material of a complex in which graphite material and silicon or silicon composite are coated with amorphous carbon material, and a cyclic carbonic acid ester derivative having fluoride atom and a sulfur-containing composite having cyclic structure are added to the non-aqueous electrolyte.

Non-aqueous electrolyte secondary battery

Non-aqueous electrolyte secondary battery

Non-aqueous electrolyte secondary battery

Owner:SANYO ELECTRIC CO LTD

Preparation method for moisture-absorbing and flame-retardant polyester fiber

InactiveCN103012765AGood hygroscopicityImprove flame retardant performanceMonocomponent copolyesters artificial filamentFiberMoisture

The invention provides moisture-absorbing and flame-retardant copolyester, which comprises terephthalic acid (PTA), other aromatic dicarboxylic acid or ester derivatives, aliphatic diol containing C2 to C6 atoms, a phosphorus flame retardant, moisture-adsorption group containing monomers, copolymer which is polymerized by flexible-chain monomers and contains ether bonds, a heat stabilizer and an anti-oxidation and uvioresistant additive. The textile fabric, which is prepared by spinning the synthesized moisture-absorbing and flame-retardant copolyester, has favorable moisture-absorbing and flame-retardant functions, and greatly improves the wearing comfort and safety flame retardancy of the polyester fabric.

Preparation method for moisture-absorbing and flame-retardant polyester fiber

Preparation method for moisture-absorbing and flame-retardant polyester fiber

Preparation method for moisture-absorbing and flame-retardant polyester fiber

Owner:BEIJING INSTITUTE OF CLOTHING TECHNOLOGY

Cellulose interpolymers and method of oxidation

ActiveUS7879994B2Decreasing and preventing frequencyPowder deliverySugar derivativesCarbon–carbon bondAcid value

This invention provides cellulose ester interpolymers, and methods of oxidizing cellulose interpolymers and cellulose ester interpolymers. The invention also provides routes to access carboxylated cellulose ester derivatives with high acid numbers wherein the carboxyl group is attached directly to the cellulose backbone by a carbon-carbon bond. Through functionalization of an intermediate aldehyde, the corresponding cationic or zwitterionic cellulose ester derivatives can also be accessed. The interpolymers of the present invention have a number of end-use applications, for example, as binder resins in various types of coating compositions and as drug delivery agents.

Cellulose interpolymers and method of oxidation

Cellulose interpolymers and method of oxidation

Cellulose interpolymers and method of oxidation

Owner:EASTMAN CHEM CO

Phosphonate ester derivatives and methods of synthesis thereof

ActiveUS8569321B2High yieldBiocideOrganic active ingredientsPurification methodsMedicinal chemistry

The disclosure describes methods of synthesis of phosphonate ester derivatives. Preferred methods according to the disclosure allow for large-scale preparation of phosphonate ester compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of phosphonate ester derivatives without the use of chromatographic purification methods and in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of phosphonate ester derivatives.

Phosphonate ester derivatives and methods of synthesis thereof

Phosphonate ester derivatives and methods of synthesis thereof

Phosphonate ester derivatives and methods of synthesis thereof

Owner:EMERGENT BIODEFENSE OPERATIONS LANSING LLC

Silybin esters derivatives and preparation and use thereof

InactiveCN1990484AOrganic active ingredientsOrganic chemistryViral illnessViral hepatitis b

The invention relates to a silibinin monoester derivative and its medicine salt or solvates. The invention also relates to its preparation method and its drug combination and medical application. The compound can inhibit activity of hepatitis b virus, so it is expected to be used as drug to treat hepatitis b virus and relevant virus diseases. The compound can protect liver and is expected to be used as drug preventing liver damage. The compound possesses effect anti free radical and is expected to be used as drug treating diseases caused by free radical.

Silybin esters derivatives and preparation and use thereof

Silybin esters derivatives and preparation and use thereof

Silybin esters derivatives and preparation and use thereof

Owner:ZHEJIANG HISUN PHARMA CO LTD

Self limiting catalyst composition and propylene polymerization process

ActiveUS20070027275A1Poor surfaceOrganic-compounds/hydrides/coordination-complexes catalystsCatalyst activation/preparationElectron donorCarboxylic acid

A catalyst composition for the polymerization of propylene comprising one or more Ziegler-Natta procatalyst compositions comprising one or more transition metal compounds and one or more esters of aromatic dicarboxylic acid internal electron donors; one or more aluminum containing cocatalysts; a selectivity control agent (SCA) comprising at least one silicon containing compound containing at least one C1-10 alkoxy group bonded to a silicon atom, and one or more activity limiting agent (ALA) compounds comprising one or more aliphatic or cycloaliphatic carboxylic acids; alkyl-, cycloalkyl- or alkyl(poly)(oxyalkyl)-(poly)ester derivatives thereof; or inertly substituted derivatives of the foregoing.

Self limiting catalyst composition and propylene polymerization process

Owner:WR GRACE & CO CONN

Conductive roller, process cartridge and image forming apparatus

InactiveUS6558781B1Plastic/resin/waxes insulatorsSynthetic resin layered productsPolymer scienceAmmonium compounds

An electroconductive roller is capable of exhibiting stable conductivity regardless of environmental change and is accompanied by small bleed-out of additives. The conductive roller includes an electroconductive support, an electroconductive elastic layer coating the support and a resistance layer coating the elastic layer; wherein the elastic layer comprises at least one species of rubber selected from the group consisting of acrylonitrile-butadiene rubber, epichlorohydrin rubber and chloroprene rubber, an ether oxygen containing alkyl phthalate derivative, a quaternary ammonium perchlorate compound and a fatty oil, and the ether oxygen-containing alkyl phthalate derivative, quaternary ammonium perchlorate compound and fatty oil are contained in a total amount of 0.1-20 wt. parts per 100 wt. parts of the rubber. The conductive roller is suitably used as a contact charging member in an electrophotographic apparatus.

Conductive roller, process cartridge and image forming apparatus

Conductive roller, process cartridge and image forming apparatus

Conductive roller, process cartridge and image forming apparatus

Owner:CANON KK

Phosphate derivatives of pharmaceutical products

InactiveUS20070042999A1Quick conversionReduce solubilityBiocideNervous disorderAnesthetic AgentPhosphate

According to the invention, there is provided a complex of a pharmaceutical compound selected from the group consisting of opioids, hormones, anaethetics and chemotherapeutic agents comprising the reaction product of: (a) one or more phosphate derivatives of one or more opioids, steroid hormones, thyroid hormones, anaesthetics or chemotherapeutic agents having a phenolic, primary alcohol, secondary alcohol or tertiary hydroxyl group; and (b) a complexing agent selected from the group comprising amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these amino acids.

Phosphate derivatives of pharmaceutical products

Owner:VITAL HEALTH SCIENCES PTY LTD

Popular searches

Ester derivatives Statin Chemistry Omega 3 fatty acid Solvent system Combination Product Triglyceride EPA - Eicosapentaenoic acid Pharmacology Hyperlipidemia

Who we serve

R&D Engineer
R&D Manager
IP Professional

Why Eureka

Industry Leading Data Capabilities
Powerful AI technology
Patent DNA Extraction

Social media

Try Eureka

PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap